TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05854953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hawley retainers in dry storage condition
Description: Three months later, an exchange of storage methods from dry to wet conditions will take place.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hawley retainers in wet storage condition
Description: Three months later, an exchange of storage methods from wet to dry conditions will take place.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VFRs in dry storage condition
Description: Three months later, an exchange of storage methods from dry to wet conditions will take place.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VFRs in wet storage condition
Description: Three months later, an exchange of storage methods from wet to dry conditions will take place.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baseline characteristics
Description: Hawley retainers and VFRs that are newly constructed will be used as baseline samples. The samples will be taken for microbial, physical and mechanical tests.
Study: NCT05500300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neo-Russian
Description: Subjects will receive Neo-Russian electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aussie
Description: Subjects will receive Aussie electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RBS
Description: Subjects will receive RBS electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RBS-IPI
Description: Subjects will receive RBS-IPI electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFEM
Description: Subjects will receive HIFEM electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction.
Study: NCT06501326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat
Description: After randomization, the control group was treated with lifestyle intervention + orlistat until the end of follow-up. Trial group 1 was treated with lifestyle intervention + liraglutide. Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.
Study: NCT05797844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active implementational educational strategy
Description: 4 follow-up visits (active implemantation strategy) were carried out for ETT cuff pressure management using the one-on-one demonstration technique every 21 days. These follow-ups included adherence to evidence-based guidelines, nurses' application of endotracheal cuff pressure measurement and solving the problems encountered during its implementation. Uncertainties associated with evidence-based guidance on endotracheal tube cuff pressure control were clarified during these sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive implementational educational strategy
Description: Theoretical training on endotracheal tube cuff pressure management through a 4-hour presentation prepared with evidence-based guide and literature. A PowerPoint presentation including endotracheal tube cuff pressure normal values, complications related to endotracheal tube cuff pressure, management of endotracheal tube cuff pressure, endotracheal tube cuff pressure control methods, methods affecting endotracheal tube cuff pressure, how to measure endotracheal tube cuff pressure was made.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive implementational educational strategy
Description: Theoretical training on endotracheal tube cuff pressure management through a 4-hour presentation prepared with evidence-based guide and literature. A PowerPoint presentation including endotracheal tube cuff pressure normal values, complications related to endotracheal tube cuff pressure, management of endotracheal tube cuff pressure, endotracheal tube cuff pressure control methods, methods affecting endotracheal tube cuff pressure, how to measure endotracheal tube cuff pressure was made.
Study: NCT04689152

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellgram-LC
Description: Patients will receive single injection of Cellgram-LC(mesenchymal stem cell) hepatic artery.
Study: NCT06279702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SERIOUS GAME
Description: Students will play serious game that about first aid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMICS
Description: students will learn comics that about first aid.
Study: NCT05896787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104, nab-paclitaxel, carboplatin
Description: AK104 plus nab-paclitaxel and carboplatin as neoadjuvant therapy，and AK104 as adjuvant therapy for those who do not achieve pCR;
Study: NCT06427694

Intervention type: DRUG
Intervention: Aldesleukin
Description: IL2 antagonist

Intervention type: DRUG
Intervention: Dextrose 5% in water
Description: matched placebo to active
Study: NCT04798040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold application
Description: To reduce pain, cold application is applied around the drain before the drain is removed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lavender oil inhalation
Description: To reduce pain, lavender oil is inhaled prior to drain removal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen administration
Description: To reduce pain, oxygen is inhaled prior to drain removal.
Study: NCT05553275

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Blood sugar evaluation (accuchecks) every four hours in latent labor and every 2 hours in active labor.Participants will be routinely managed with maintenance fluids of lactated ringers during latent labor and lactated ringers with dextrose 5% in active labor. Blood sugars of more than 110 mg/dl at any time point in labor will be treated with an insulin drip as follows:~Regular insulin (100 units) in 100cc of normal saline, with Lactated Ringers with 5% dextrose at 125cc/hour. If blood sugar 111-140, insulin drip at 1 unit/hour will be given and continued if blood sugar is 111-140.If blood sugar is 141-180, then drip will be changed to to 1.5 unit/hour and if blood sugar is 181-220, drip will be changed to 2.0 units/hour and MD will be called if blood sugar is more than 221 mg/dl

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Permissive intrapartum glucose control
Description: Blood sugar evaluation (accuchecks) every four hours in latent labor and every 2 hours in active labor.Participants will be routinely management with maintenance fluids of lactated ringers during latent labor and lactated ringers with dextrose 5% in active labor.Blood sugars of more than 180 mg/dl at any time point in labor will be treated with an insulin drip as follows:~Regular insulin (100 units) in 100cc of normal saline, with Lactated Ringers with 5% dextrose at 125cc/hour.If blood sugar is 181-200, insulin drip at 1 unit/hour will be given. If blood sugar is 201-220, then drip will be changed to 1.5 units/hour. If blood sugar is 221 - 250, then drip will be changed to 2.0 units/hour and if blood sugar is more than 251 MD will be called.
Study: NCT05208775

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PDT
Description: Drug: (Hematoporphyrin sodium injection) Hematoporphyrin sodium injection (xibofen):2mg/kg I.V.~Laser irradiation:~48 hours after the patient input the photosensitizer, the laser irradiation time is 900 seconds, and the output power is 200 watts.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESD
Description: The patients received standard endoscopic submucosal dissection after enrollment.
Study: NCT05116605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM)
Description: Photobiomodulation (PBM) is light therapy in both the visible and near-infrared range (non-UV). This light is absorbed through the skin and functions at the cellular level, providing a lowering of inflammation and oxidative stress. Participants will undergo 20 minute sessions three times a week for 4 weeks using the NovoTHOR as the only intervention.
Study: NCT05780333

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TAP block
Description: Bilateral tap block with 20 ml of mixture 2:1:1 (0.5% bupivacaine: 0.9%NaCl: 2% lidocain) for each

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP block
Description: Bilateral esp block with 20 ml of mixture 2:1:1 (0.5% bupivacaine: 0.9%NaCl: 2% lidocain) for each
Study: NCT04905940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Turmeric mouthwash
Description: Turmeric mouthwash evaluation in controlling halitosis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Turmeric mouthwash
Description: Turmeric mouthwash evaluation in controlling halitosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Turmeric mouthwash
Description: Turmeric mouthwash evaluation in controlling halitosis
Study: NCT04683224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-612
Description: 100 µg \[microgram\] of an experimental study vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-612
Description: 100 µg \[microgram\] of an experimental study vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-612
Description: 100 µg \[microgram\] of an experimental study vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-612
Description: 100 µg \[microgram\] of an experimental study vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a 0.9% sodium chloride (normal saline) injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a 0.9% sodium chloride (normal saline) injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a 0.9% sodium chloride (normal saline) injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a 0.9% sodium chloride (normal saline) injection
Study: NCT05534061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect2Test
Description: Brief motivational enhancement intervention to improve the likelihood of testing and vaccination among syringe exchange clients

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Connect2Test
Description: Brief motivational enhancement intervention to improve the likelihood of testing and vaccination among syringe exchange clients
Study: NCT05577195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella
Description: To provide active left ventricular unloading in the experimental arm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VA-ECMO
Description: To provide circulatory support in both arms

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VA-ECMO
Description: To provide circulatory support in both arms
Study: NCT05430217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: 1 tablet (15 mg) once per day for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo tablet once per day for 28 days
Study: NCT06292221

Intervention type: OTHER
Group type: OTHER
Intervention: A mobile Health (mHealth) tool called 'DepWatch'
Description: The mobile Health (mHealth) tool 'DepWatch' developed by the study team consists of the DepWatch app that is uploaded on participant's smart phones with their consent and a Fitbit provided to the participants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A mobile Health (mHealth) tool called 'DepWatch'
Description: The mobile Health (mHealth) tool 'DepWatch' developed by the study team consists of the DepWatch app that is uploaded on participant's smart phones with their consent and a Fitbit provided to the participants
Study: NCT06241469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab,nab-paclitaxel and tegio
Description: Immunotherapy combined with chemotherapy
Study: NCT05698433

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06602960

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Accurate Sleep Data Feedback
Description: Participants will receive accurate feedback about their sleep data.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inflated Sleep Data Feedback
Description: Participants will receive inflated feedback about their sleep data, suggesting better sleep quality than detected by Fitbit (actual sleep hours +10%).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deflated Sleep Data Feedback
Description: Participants will receive deflated feedback about their sleep data, suggesting poorer sleep quality than detected by Fitbit (actual sleep hours -10%).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accurate Sleep Data Feedback + Sleep-related Educational Information
Description: Participants will receive accurate feedback about their sleep data along with sleep-related educational information.
Study: NCT06598241

Intervention type: DEVICE
Intervention: Borate-base Bioactive Glass Fiber Matrix (BBGFM)
Description: Bioactive glass materials are biocompatible water-soluble inorganic ceramic materials that release their constituent ions when immersed in body fluids.
Study: NCT06622642

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transoral technique for mandibular angle fracture reduction
Description: In transoral technique approach inferior alveolar nerve block and buccal nerve block will be given by 2% xylocaine with 1:100000 adrenaline. Incision will be made with surgical blade no 15 from gingival crevices of molars to ascending ramus. Fracture segments will be reduced alongwith MMF. A 5-hole 2mm miniplate with 2 holes anterior and 2 holes posterior to fracture line will be screwed to external oblique ridge and MMF will be removed and incision line will be closed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transbuccal technique for mandibular angle fracture reduction
Description: In transbuccal technique inferior alveolar nerve block and buccal nerve block will be given by 2% xylocaine with 1:100000 adrenaline. Incision will be made with surgical blade no 15 from gingival crevices of molars to ascending ramus. Fracture segments will be reduced alongwith MMF. extraorally a stab incision will be made with scalpel blade parallel to relaxed resting skin tension lines through which the cannula with a trocar will be inserted through facial tissue down to bone. Transbuccal instrument system will cionsist of transbuccal guide, mountable retractor, drill sleeve, drill guide, and 2mm drill bit. A 2mm titanium miniplate will be placed along buccal cortex and screwed through trocar system. MMF will be removed and incision line closed
Study: NCT06632704

Intervention type: DEVICE
Intervention: Colgate Toothbrush assist
Description: toothbrush handle assignment to all subjects; subjects will have a choice between two brush heads
Study: NCT06633835

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: protein subunit: Novavax COVID-19 vaccine
Description: Participants will receive a single dose (0.5 ml) of study vaccine Novavax COVID-19 vaccine, 2024-2025 formula (JN.1 containing) in the deltoid muscle of the arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pfizer mRNA COVID-19 vaccine
Description: Participants will receive a single dose (0.3 ml) of study vaccine Pfizer mRNA COVID-19 vaccine, 2024-2025 formula (KP.2 containing) in the deltoid muscle of the arm.
Study: NCT05149326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: KN046+Nab-Paclitaxel+Gemcitabine In combine therapy stage, KN046 is 5 milligram per kilogram, every 2 weeks. In maintain stage, KN046 is 5 milligram per kilogram, every 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo+Nab-Paclitaxel+Gemcitabine In combine therapy stage, placebo is 5 milligram per kilogram, every 2 weeks. In maintain stage, placebo is 5 milligram per kilogram, every 2 weeks.
Study: NCT05961917

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5 cmH2O Positive end-expiratory pressure (PEEP)
Description: PEEP will be set at 5 cmH2O
Study: NCT04946617

Intervention type: DRUG
Intervention: undefined
Description: Rinsing with mouthwashes

Intervention type: DRUG
Intervention: undefined
Description: Rinsing with mouthwashes

Intervention type: DRUG
Intervention: undefined
Description: Rinsing with mouthwashes
Study: NCT05772078

Intervention type: OTHER
Intervention: Assess compliance rate and demographics
Description: Records to evaluate attendance rate

Intervention type: OTHER
Intervention: Assess compliance rate and demographics
Description: Records to evaluate attendance rate

Intervention type: OTHER
Intervention: Assess compliance rate and demographics
Description: Records to evaluate attendance rate
Study: NCT04788771

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Tracheal intubation in laparoscopic extraperitoneal hernia repair
Description: laryngeal mask airway in laparoscopic extraperitoneal hernia repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation in laparoscopic extraperitoneal hernia repair
Description: laryngeal mask airway in laparoscopic extraperitoneal hernia repair
Study: NCT05961917

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10 cmH2O Positive end-expiratory pressure (PEEP)
Description: PEEP will be set at 10 cmH2O
Study: NCT04100434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Patients were randomly assigned of the ratio of 1:1 using a computer-generated random number and divided into two treatment groups: the statin alone therapy and the evolocumab plus statin therapy.
Study: NCT05236712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile app
Description: The app sends reminder 'push' notifications to complete weekly surveys. The survey is a series of questions about foods and drinks participants had in the last week. Once the weekly survey is completed the app generates a personalized weekly report showing foods we encourage participants to eat more of, eat less of, or keep eating the same amount of. The app will also show menu recommendations for breakfast, lunch, dinner, and snacks that will help participants to eat healthier. Finally, the app also has a feature that allows chatting with the research team by sending and receiving in-app texts.
Study: NCT05013970

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical assessment
Description: Clinical assessment including Visual Analog Scale (VAS) for Knee Pain, and Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: Radiographic imaging
Description: MRI of the knee
Study: NCT05153707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discharge Education Program
Description: medication reconciliation, medication review, individually prepared patient medicine (pill) card, patient education (based on Health Belief Model by using written material and video, and verbally \[by using Teach back method especially for patients with low health literacy\]) and counseling (using behavior change techniques based on The Capability, Opportunity, and Motivation Behavior model).
Study: NCT04795700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MSC intervention
Description: Patients in the intervention group had access to conventional care, in addition to receiving the 8 weeks MSC intervention sessions. The intervention was provided by trained nurses, including one researcher and one MSC therapist. The intervention is mainly out-of-hospital intervention, supplemented by short-term in-hospital intervention. Among them, the first and second weeks of the intervention project in the hospital phase focus on guiding the research subjects to understand the content of mindful self-compassion and emotions, and carry out basic mindful self-compassion training; the content of the 3-8th week of the intervention program outside the hospital, Focus on the maintenance of mindful self-compassion training and the promotion of mindful life. Each face-to-face group contact lasted about 1 hour, depending on the complexity of the patients' problems.
Study: NCT05501314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early discharge with remote home monitoring.
Description: After at least 48 hours of hospital admission, patients are discharged early with the use of remote home monitoring. During home monitoring, heartrate, respiratory rate, posture and movement are monitored every 5 minutes for at least 4 days, using a wearable sensor. Core temperature is monitored using an ear thermometer. Patients are contacted once per day by a nurse from the Virtual Monitoring Centre (VMC) to assess pancreatitis related complaints, intake of fluids and food, pain and the use of analgesics. Patients are asked to provide information to the hospital using a smartphone app.
Study: NCT05703659

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. longum subsp. infantis
Description: Infants will receive 1 dose of a B. infantis probiotic daily for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. reuteri probiotic
Description: Infants will receive 1 dose of an L. reuteri probiotic daily for 4 weeks